Experts hailed exciting news for some people with sickle cell disease in England as the health watchdog decided to grant ...

The UK’s Medicines and Healthcare Regulatory Agency (MHRA) approved Casgevy for sickle cell disease in 2023, followed by ...

A £1.65 million treatment has been approved for use for some NHS patients, offering some with an inherited blood disorder ...

Australian cancer researchers are the first to establish a next-generation gene-editing tool for modeling and interrogating ...

This new tool, known as minimal, versatile genetic perturbation technology (mvGPT), combines the powers of gene editing, ...

NanoCas, an ultracompact nuclease, enables efficient muscle editing in NHPs using a single AAV - advancing gene editing for hard-to-target tissues.

Australian researchers have successfully introduced an improved version of Cas12a gene-editing enzyme in mice.

Advances in CRISPR technologies promise to accelerate the burgeoning pipeline of gene-editing therapies and broaden access to these disease-altering therapies.

Australian cancer researchers are the first to establish a next-generation gene-editing tool for modelling and interrogating human disease.

PFG Investments LLC lifted its stake in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 9.9% in the 4th quarter, ...

Australian cancer researchers are the first to establish a next-generation gene-editing tool for modelling and interrogating human disease.A novel ...